January
Monday 1 January 2018 photo 8/15
|
Atp 3 guidelines for statins: >> http://suc.cloudz.pw/download?file=atp+3+guidelines+for+statins << (Download)
Atp 3 guidelines for statins: >> http://suc.cloudz.pw/read?file=atp+3+guidelines+for+statins << (Read Online)
atp guidelines 2017
atp iii guidelines 2015
atp iv guidelines 2017
atp iv guidelines 2016
ncep atp iii metabolic syndrome
ncep guidelines 2017
atp iv guidelines at a glance
atp iv guidelines 2015
15 Jul 2015 In a new study, researchers compared the National Cholesterol Education Program's 2004 Updated Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the 2013 American College of Cardiology/American Heart Association (ACC/AHA)
iii. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood. Cholesterol in Adults (Adult Treatment Panel III). Members: Scott M. Grundy, . Relation of ATP III to other clinical guidelines . Categories and classification of total cholesterol and LDL cholesterol . . . . . . . . . 3.
Can recent statin trials and the NCEP ATP III revised guidelines result in many more patients receiving statins of proven benefit and reassuring adverse event profiles?
In 1988, the National. Cholesterol Education. Program (NCEP) identi- fied low-density lipopro- tein cholesterol (LDL C) as its main target and empha- sized primary coronary heart disease (CHD) pre- vention with a goal of LDL C < 130 mg/dl. In 1993, LDL C remained the main target but there was a new focus on secondary
Each of the guideline reports—ATP I, II, and III—has a major thrust. ATP I outlined a strategy for primary prevention of coronary heart disease (CHD) in persons with high levels of low density lipoprotein (LDL) cholesterol ( 160 mg/dL) or those with borderline-high LDL cholesterol (130-159 mg/dL) and multiple (2+) risk factors
1 Mar 2002 The NCEP–ATP III guidelines are similar to those in the second report in identifying LDL as a primary target of cholesterol-lowering therapy. Risk stratification continues to determine LDL goals and the intensity of LDL-lowering therapy. Dietary therapy remains the first line of treatment, with drug therapy
18 Dec 2013 The new guidelines have abandoned LDL targets of therapy in favor of simply using a dose of statin to treat the patient. But is the achieved risk reduction adequate? ATP III helps the clinician answer this crucial question by reference to the LDL goal, but the new guidelines are agnostic on this point.
3 May 2016 The LDL-C target for the intermediate-risk group is <130 mg/dL. Therefore, he would not be recommended to receive statin therapy. The 2013 ACC/AHA guideline differs substantially from its previous version, the ATP III guidelines, and other leading international guidelines.
Overall, 2135 participants (57%) qualified for statin treatment according to the ACC/AHA guidelines as compared with 1583 (42%) under the ATP III guidelines. Additional participants qualifying under the ACC/AHA guideline were more likely to be male, older in age, have a lower LDL cholesterol, and without known
Annons
Visa toppen
Show footer